GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,

SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Kendrick Sparks, PGY3 September 17, 2015

Results of the GLAGOV Trial

Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV Trial SJ Nicholls, H Kassahun, DM Brennan,

NICE –CG 181 Continuum of CVD Risk and its treatment

Results of the GLAGOV Trial

Do PCSK9 Inhibitors Cause Cognitive Impairment?

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

The ASSERT Study.

An Endocrinology Clinic in Dyslipidemia

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

An Update on PCSK9 Inhibitors

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Radical New Concepts in Lipid Management

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

After Eighty Study Trial design: Elderly patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) were randomized to invasive therapy (n = 229)

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Screening, Lipid Stabilization, and Placebo Run-in

Efficacy and safety of niacin/laropiprant

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Reducing Risk for CV Outcomes

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

Stephen J. Nicholls, MBBS, PhD; E

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Flow of Patients Through the Trial

Flow of Patients Through Trial

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Baseline Characteristics, Blood Pressures, and Laboratory Values

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Achieving Lipid Targets With PCSK9 Inhibition

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

(p for noninferiority = 0.01)

PCSK9 Inhibitors and Real-World Evidence

LDL is causal of atherosclerosis Evidence from meta-analyses of Mendelian randomization studies, prospective cohort studies, and randomized controlled.

Presentation transcript:

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous placebo (n = 486). Results (p < 0.001) Nominal change in percent atheroma volume at 78 weeks: -0.95% in the evolocumab group vs. 0.05% in the placebo group (p < 0.001 for between-group comparison) Patients with plaque regression: 64.3% with evolocumab vs. 47.3% with placebo (p < 0.001) Major adverse cardiac events: 12.2% with evolocumab vs. 15.3% with placebo 0.05 % Conclusions -0.95 Among patients with angiographic evidence of CAD on chronic statin therapy, the PCSK9 inhibitor evolocumab resulted in a greater change in percent atheroma volume and a greater proportion of patients with plaque regression Nominal change in % atheroma volume Evolocumab Placebo Nicholls SJ, et al. JAMA 2016;316:2373-84